ParkinsonFranceV1, Main, Exploration, bibRecordById, pubmed:11748743

Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6‐OHDA lesion in the rat brain

Identifieur interne : 003665 ( Main/Exploration ); précédent : 003664; suivant : 003666

Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6‐OHDA lesion in the rat brain

Auteurs : Oum-Kaltoum Hassani [France] ; Mireille Mouroux [France] ; Georg Andrees Bohme [France] ; Jean-Marie Stutzmann [France] ; Jean Féger [France]

Source :

Movement Disorders [ 0885-3185 ] ; 2001-11.

RBID : ISTEX:316494D7CE943C7950A59D8A9E335C733DD1C046

Descripteurs français

Pascal (Inist)
- Animal, Benzothiazole, Canal ionique, Chimiothérapie, Excitotoxicité, Inhibiteur, Mécanisme action, Neurone dopaminergique, Neuroprotecteur, Noyau sousthalamique, Parkinson maladie, Pathologie expérimentale, Rat, Riluzole, Sodium, Traitement.
Wicri :
- topic : Sodium.

English descriptors

KwdEn :
- Adrenergic Agents, Animal, Animals, Benzothiazole, Chemotherapy, Dopaminergic neuron, Excitatory Amino Acid Antagonists (pharmacology), Excitotoxicity, Experimental disease, Functional Laterality, Inhibitor, Ionic channel, Male, Mechanism of action, Models, Animal, Neurons (drug effects), Neuroprotective Agents (pharmacology), Neuroprotective agent, Oxidopamine, Parkinson Disease (physiopathology), Parkinson Disease, Secondary (chemically induced), Parkinson disease, Parkinson's disease, Rat, Rats, Rats, Sprague-Dawley, Riluzole, Riluzole (pharmacology), Sodium, Sodium Channel Blockers (pharmacology), Substantia Nigra (drug effects), Substantia Nigra (pathology), Subthalamic Nucleus (drug effects), Subthalamic Nucleus (pathology), Subthalamic Nucleus (physiopathology), Subthalamic nucleus, Treatment, basal ganglia, excitotoxicity, glutamate release, neurodegenerative diseases, neuroprotection, sodium channels blockers.
MESH :
- chemical , pharmacology : Excitatory Amino Acid Antagonists, Neuroprotective Agents, Riluzole, Sodium Channel Blockers.
- chemical : Adrenergic Agents, Oxidopamine.
- chemically induced : Parkinson Disease, Secondary.
- drug effects : Neurons, Substantia Nigra, Subthalamic Nucleus.
- pathology : Substantia Nigra, Subthalamic Nucleus.
- physiopathology : Parkinson Disease, Subthalamic Nucleus.
- Animals, Functional Laterality, Male, Models, Animal, Rats, Rats, Sprague-Dawley.

Abstract

An abnormal increase in the activity of neurons of the subthalamic nucleus is a key pathophysiological feature of Parkinson's disease. We sought to determine whether riluzole, a sodium channel inhibitor that interferes with glutamatergic neurotransmission, affects neuronal activity in this brain region. Intravenous administration of riluzole reduced the discharge rate of subthalamic neurons in rats with 6‐OHDA‐induced lesions of the midbrain. By contrast, no effect was observed in nonlesioned control animals. This property may contribute to the neuroprotective effects of riluzole in animal models of PD through the modulation of the glutamatergic inputs these neurons feedback to nigral dopaminergic neurons. © 2001 Movement Disorder Society.

Url:

https://api.istex.fr/document/316494D7CE943C7950A59D8A9E335C733DD1C046/fulltext/pdf

DOI: 10.1002/mds.1219

Affiliations:

Le document en format XML

<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6‐OHDA lesion in the rat brain</title>
<author><name sortKey="Hassani, Oum Altoum" sort="Hassani, Oum Altoum" uniqKey="Hassani O" first="Oum-Kaltoum" last="Hassani">Oum-Kaltoum Hassani</name>
</author>
<author><name sortKey="Mouroux, Mireille" sort="Mouroux, Mireille" uniqKey="Mouroux M" first="Mireille" last="Mouroux">Mireille Mouroux</name>
</author>
<author><name sortKey="Bohme, Georg Andrees" sort="Bohme, Georg Andrees" uniqKey="Bohme G" first="Georg Andrees" last="Bohme">Georg Andrees Bohme</name>
</author>
<author><name sortKey="Stutzmann, Jean Arie" sort="Stutzmann, Jean Arie" uniqKey="Stutzmann J" first="Jean-Marie" last="Stutzmann">Jean-Marie Stutzmann</name>
</author>
<author><name sortKey="Feger, Jean" sort="Feger, Jean" uniqKey="Feger J" first="Jean" last="Féger">Jean Féger</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:316494D7CE943C7950A59D8A9E335C733DD1C046</idno>
<date when="2001" year="2001">2001</date>
<idno type="doi">10.1002/mds.1219</idno>
<idno type="url">https://api.istex.fr/document/316494D7CE943C7950A59D8A9E335C733DD1C046/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000668</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000668</idno>
<idno type="wicri:Area/Istex/Curation">000668</idno>
<idno type="wicri:Area/Istex/Checkpoint">000E76</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000E76</idno>
<idno type="wicri:doubleKey">0885-3185:2001:Hassani O:riluzole:reduces:hyperactivity</idno>
<idno type="wicri:Area/Main/Merge">003C43</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:02-0176575</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001147</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000289</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001032</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">001032</idno>
<idno type="wicri:doubleKey">0885-3185:2001:Hassani O:riluzole:reduces:hyperactivity</idno>
<idno type="wicri:Area/Main/Merge">003D88</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:11748743</idno>
<idno type="wicri:Area/PubMed/Corpus">001227</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001227</idno>
<idno type="wicri:Area/PubMed/Curation">001186</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001186</idno>
<idno type="wicri:Area/PubMed/Checkpoint">001186</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001186</idno>
<idno type="wicri:Area/Ncbi/Merge">000217</idno>
<idno type="wicri:Area/Ncbi/Curation">000217</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000217</idno>
<idno type="wicri:doubleKey">0885-3185:2001:Hassani O:riluzole:reduces:hyperactivity</idno>
<idno type="wicri:Area/Main/Merge">003B21</idno>
<idno type="wicri:Area/Main/Curation">003665</idno>
<idno type="wicri:Area/Main/Exploration">003665</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6‐OHDA lesion in the rat brain</title>
<author><name sortKey="Hassani, Oum Altoum" sort="Hassani, Oum Altoum" uniqKey="Hassani O" first="Oum-Kaltoum" last="Hassani">Oum-Kaltoum Hassani</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Pharmacologie, Faculté de Sciences Pharmaceutiques et Biologiques, Université René Descartes, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Mouroux, Mireille" sort="Mouroux, Mireille" uniqKey="Mouroux M" first="Mireille" last="Mouroux">Mireille Mouroux</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Pharmacologie, Faculté de Sciences Pharmaceutiques et Biologiques, Université René Descartes, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Bohme, Georg Andrees" sort="Bohme, Georg Andrees" uniqKey="Bohme G" first="Georg Andrees" last="Bohme">Georg Andrees Bohme</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Aventis Pharma France S.A., Neurodegenerative Disease Group, Centre de Recherches de Paris</wicri:regionArea>
<wicri:noRegion>Centre de Recherches de Paris</wicri:noRegion>
<wicri:noRegion>Centre de Recherches de Paris</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Stutzmann, Jean Arie" sort="Stutzmann, Jean Arie" uniqKey="Stutzmann J" first="Jean-Marie" last="Stutzmann">Jean-Marie Stutzmann</name>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Aventis Pharma France S.A., Neurodegenerative Disease Group, Centre de Recherches de Paris</wicri:regionArea>
<wicri:noRegion>Centre de Recherches de Paris</wicri:noRegion>
<wicri:noRegion>Centre de Recherches de Paris</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Feger, Jean" sort="Feger, Jean" uniqKey="Feger J" first="Jean" last="Féger">Jean Féger</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Laboratoire de Pharmacologie, Faculté de Sciences Pharmaceutiques et Biologiques, Université René Descartes, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U‐289, Hopital de la Salpêtrière, Paris</wicri:regionArea>
<placeName><region type="region">Île-de-France</region>
<region type="old region">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>INSERM U‐289, Hôpital de la Salpêtrière, 47 Boulevard de l'Hôpital, 75651 Paris Cedex 13</wicri:regionArea>
<placeName><region type="region" nuts="2">Île-de-France</region>
<settlement type="city">Paris</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>John Wiley & Sons, Inc.</publisher>
<pubPlace>New York</pubPlace>
<date type="published" when="2001-11">2001-11</date>
<biblScope unit="volume">16</biblScope>
<biblScope unit="issue">6</biblScope>
<biblScope unit="page" from="1110">1110</biblScope>
<biblScope unit="page" to="1114">1114</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">316494D7CE943C7950A59D8A9E335C733DD1C046</idno>
<idno type="DOI">10.1002/mds.1219</idno>
<idno type="ArticleID">MDS1219</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adrenergic Agents</term>
<term>Animal</term>
<term>Animals</term>
<term>Benzothiazole</term>
<term>Chemotherapy</term>
<term>Dopaminergic neuron</term>
<term>Excitatory Amino Acid Antagonists (pharmacology)</term>
<term>Excitotoxicity</term>
<term>Experimental disease</term>
<term>Functional Laterality</term>
<term>Inhibitor</term>
<term>Ionic channel</term>
<term>Male</term>
<term>Mechanism of action</term>
<term>Models, Animal</term>
<term>Neurons (drug effects)</term>
<term>Neuroprotective Agents (pharmacology)</term>
<term>Neuroprotective agent</term>
<term>Oxidopamine</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Parkinson Disease, Secondary (chemically induced)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Rat</term>
<term>Rats</term>
<term>Rats, Sprague-Dawley</term>
<term>Riluzole</term>
<term>Riluzole (pharmacology)</term>
<term>Sodium</term>
<term>Sodium Channel Blockers (pharmacology)</term>
<term>Substantia Nigra (drug effects)</term>
<term>Substantia Nigra (pathology)</term>
<term>Subthalamic Nucleus (drug effects)</term>
<term>Subthalamic Nucleus (pathology)</term>
<term>Subthalamic Nucleus (physiopathology)</term>
<term>Subthalamic nucleus</term>
<term>Treatment</term>
<term>basal ganglia</term>
<term>excitotoxicity</term>
<term>glutamate release</term>
<term>neurodegenerative diseases</term>
<term>neuroprotection</term>
<term>sodium channels blockers</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Excitatory Amino Acid Antagonists</term>
<term>Neuroprotective Agents</term>
<term>Riluzole</term>
<term>Sodium Channel Blockers</term>
</keywords>
<keywords scheme="MESH" type="chemical" xml:lang="en"><term>Adrenergic Agents</term>
<term>Oxidopamine</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Parkinson Disease, Secondary</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Neurons</term>
<term>Substantia Nigra</term>
<term>Subthalamic Nucleus</term>
</keywords>
<keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Substantia Nigra</term>
<term>Subthalamic Nucleus</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Parkinson Disease</term>
<term>Subthalamic Nucleus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Functional Laterality</term>
<term>Male</term>
<term>Models, Animal</term>
<term>Rats</term>
<term>Rats, Sprague-Dawley</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Animal</term>
<term>Benzothiazole</term>
<term>Canal ionique</term>
<term>Chimiothérapie</term>
<term>Excitotoxicité</term>
<term>Inhibiteur</term>
<term>Mécanisme action</term>
<term>Neurone dopaminergique</term>
<term>Neuroprotecteur</term>
<term>Noyau sousthalamique</term>
<term>Parkinson maladie</term>
<term>Pathologie expérimentale</term>
<term>Rat</term>
<term>Riluzole</term>
<term>Sodium</term>
<term>Traitement</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Sodium</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">An abnormal increase in the activity of neurons of the subthalamic nucleus is a key pathophysiological feature of Parkinson's disease. We sought to determine whether riluzole, a sodium channel inhibitor that interferes with glutamatergic neurotransmission, affects neuronal activity in this brain region. Intravenous administration of riluzole reduced the discharge rate of subthalamic neurons in rats with 6‐OHDA‐induced lesions of the midbrain. By contrast, no effect was observed in nonlesioned control animals. This property may contribute to the neuroprotective effects of riluzole in animal models of PD through the modulation of the glutamatergic inputs these neurons feedback to nigral dopaminergic neurons. © 2001 Movement Disorder Society.</div>
</front>
</TEI>
<affiliations><list><country><li>France</li>
</country>
<region><li>Île-de-France</li>
</region>
<settlement><li>Paris</li>
</settlement>
</list>
<tree><country name="France"><region name="Île-de-France"><name sortKey="Hassani, Oum Altoum" sort="Hassani, Oum Altoum" uniqKey="Hassani O" first="Oum-Kaltoum" last="Hassani">Oum-Kaltoum Hassani</name>
</region>
<name sortKey="Bohme, Georg Andrees" sort="Bohme, Georg Andrees" uniqKey="Bohme G" first="Georg Andrees" last="Bohme">Georg Andrees Bohme</name>
<name sortKey="Feger, Jean" sort="Feger, Jean" uniqKey="Feger J" first="Jean" last="Féger">Jean Féger</name>
<name sortKey="Feger, Jean" sort="Feger, Jean" uniqKey="Feger J" first="Jean" last="Féger">Jean Féger</name>
<name sortKey="Feger, Jean" sort="Feger, Jean" uniqKey="Feger J" first="Jean" last="Féger">Jean Féger</name>
<name sortKey="Mouroux, Mireille" sort="Mouroux, Mireille" uniqKey="Mouroux M" first="Mireille" last="Mouroux">Mireille Mouroux</name>
<name sortKey="Stutzmann, Jean Arie" sort="Stutzmann, Jean Arie" uniqKey="Stutzmann J" first="Jean-Marie" last="Stutzmann">Jean-Marie Stutzmann</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003665 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003665 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    ParkinsonFranceV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     ISTEX:316494D7CE943C7950A59D8A9E335C733DD1C046
   |texte=   Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6‐OHDA lesion in the rat brain
}}

This area was generated with Dilib version V0.6.29.
Data generation: Wed May 17 19:46:39 2017. Site generation: Mon Mar 4 15:48:15 2024

La maladie de Parkinson en France (serveur d'exploration)

Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6‐OHDA lesion in the rat brain

Riluzole reduces hyperactivity of subthalamic neurons induced by unilateral 6‐OHDA lesion in the rat brain

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

	La maladie de Parkinson en France (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.